CYP2D6 genotype: impact on adverse effects and nonresponse during treatment with antidepressants-a pilot study by Rau Thomas, Wohlleben Gerlinde, Wuttke Henrike, Thuerauf Norbert, Lunkenheimer Jens, Lanczik Mario, Eschenhagen Thomas in Clinical pharmacology and therapeutics (2004).

[PMID: 15116051] PubMed


Treatment with antidepressants is frequently associated with adverse effects or insufficient clinical response. Several antidepressants are metabolized by cytochrome P450 (CYP) 2D6. The activity of this enzyme markedly varies among individuals from poor to ultrarapid metabolism on the basis of the polymorphism of the CYP2D6 gene. This association study investigated whether the CYP2D6 genotype distribution differs from that of the German white population either in patients with marked adverse effects or in nonresponders during treatment with antidepressants metabolized by CYP2D6.

[ hide abstract ]

Discussed In Paper


Variant Annotations

Sign in to see variant annotations.

Rx Annotations

No dosing information annotated.